HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists

COVID Clinical Trial

Official title:

Hospital for Special Surgery COVID-19 Antibody Serology Among Anesthesiologists and Surgeons 2020

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04389294
• Other study ID #: 2020-0850
• Status: Completed
• Phase: N/A
• Start date: May 5, 2020
• Est. completion date: September 4, 2020

Study information

• Verified date: March 2023
• Source: Hospital for Special Surgery, New York
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to understand the infectious exposure of SARS-coronavirus 2 (SARS-CoV2) among surgeons and anesthesiologists and to correlate this status with self-reported indices of COVID-19 illness.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 143
• Est. completion date: September 4, 2020
• Est. primary completion date: June 16, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Accredited to practice at HSS

• All anesthesiology and surgery faculty

• All anesthesia and orthopedic surgery fellows

• All orthopedic surgery residents

Exclusion Criteria:

• Refusal to participate in either of the interventions at either of the timepoints of interest

Related Conditions & MeSH terms

• COVID

Intervention

Diagnostic Test:
• SARS-CoV2 serum antibody testing
Participants will have SARS-CoV2 serum antibody testing performed twice within 4 months of each other.

Locations

Country	Name	City	State
United States	Hospital for Special Surgery	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Hospital for Special Surgery, New York

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Participants Who Were Eligible for in Plasma Donation	Individuals who tested positive for COVID-19 who may be eligible for convalescent plasma donation	Serology Test #1 (Study Enrollment) and Test #2 (3 months apart)
Primary	Number of Participants With SARS-CoV-2 IgG Antibodies	Prevalence of SARS-CoV-2 IgG antibodies by serology testing in participants at the time of study enrollment or 3 months later	Serology Test #1 (Study Enrollment) and Test #2 (3 months apart)
Secondary	Differences in Sex Between IgG Antibody-positive vs. Negative Participants	Secondary outcomes included differences in the survey responses between IgG antibody-positive and -negative participants. These included demographics such as sex.	Survey completed before or on day of serology testing asking about information from January 1, 2020 to May 5, 2020
Secondary	Number of Asymptomatic Participants With Positive Antibody Serology	Number of asymptomatic participants with positive antibody serology at either the study enrollment timepoint or 3 month timepoint	Serology Test #1 (Study Enrollment) and Serology Test #2 (3 months apart)
Secondary	Percentage of Antibody-positive Participants Who Subsequently Develop COVID-19	Percentage of antibody-positive participants who subsequently develop COVID-19 at either the study enrollment timepoint or the 3 months time point	Serology Test #1 (Study Enrollment) and Serology Test #2 (3 months apart)
Secondary	Differences in Race Between IgG Antibody-positive vs. Negative Participants	Secondary outcomes included differences in the survey responses between IgG antibody-positive and -negative participants. These included demographics such as race.	Survey completed before or on day of serology testing asking about information from January 1, 2020 to May 5, 2020
Secondary	Differences in Average Number of Adults in Household Between IgG Antibody-positive vs. Negative Participants	Secondary outcomes included differences in the survey responses between IgG antibody-positive and -negative participants. These included demographics such as number of adult household members.	Survey completed before or on day of serology testing asking about information from January 1, 2020 to May 5, 2020
Secondary	Differences in Comorbidities Between IgG Antibody-positive vs. Negative Participants	Secondary outcomes included differences in the survey responses between IgG antibody-positive and -negative participants. These included comorbidities.	Survey completed before or on day of serology testing asking about information from January 1, 2020 to May 5, 2020